MSD at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

MSD takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on its own pipeline, including MK-2214, an antibody against phosphorylated tau, and an alpha7 receptor modulator. Its work also covers a plasma biomarker panel for amyloid status.

Organization	CTAD 2026 Attendance
MSD Rahway, New Jersey	◇Silver Sponsor
msd.com Large pharmaSilver Sponsor Global drugmaker, known as Merck & Co. in the US and Canada; its Alzheimer's pipeline includes the anti-tau antibody MK-2214.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue A Phase 2 Randomized, Controlled Trial of MK-1167, a Positive Allosteric Modulator of the α7 nAChR, as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia (P037) Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment (P268) Blood and CSF biomarkers · Trial design and endpoints Talk Wed Nov 18 10:15am A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer’s disease: Study rationale and design Anti-amyloid and anti-tau therapies

Organization

CTAD 2026 Attendance

MSD

Rahway, New Jersey

◇Silver Sponsor

msd.com

Large pharmaSilver Sponsor

Global drugmaker, known as Merck & Co. in the US and Canada; its Alzheimer's pipeline includes the anti-tau antibody MK-2214.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

A Phase 2 Randomized, Controlled Trial of MK-1167, a Positive Allosteric Modulator of the α7 nAChR, as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia (P037)

Other mechanisms and targets

Poster

Wed Nov 18
7:15am–5:30pm

A Novel Plasma Biomarker Panel Assessed by NULISA Improves Amyloid Positivity Diagnosis Beyond pTau-217 for Clinical Trial Enrichment (P268)

Blood and CSF biomarkers · Trial design and endpoints

Talk

Wed Nov 18
10:15am

A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer’s disease: Study rationale and design

Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from MSD

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction